IMM-H014
/ Changchun Intellicrown Pharma, Shanghai Inst. of Materia Medica
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 11, 2025
To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH
(clinicaltrials.gov)
- P1/2 | N=40 | Not yet recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD
New P1/2 trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis
April 15, 2025
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=138 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Trial completion date: Dec 2024 ➔ Aug 2025 | Trial primary completion date: Jul 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
January 22, 2024
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=138 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD
New P1 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
1 to 3
Of
3
Go to page
1